Joshua Boger, founder of Vertex, appointed Chair of CervoMed Board; RewinD-LB trial on track

CervoMed Inc.

Joshua Boger, Ph.D., former CEO and founder of Vertex Pharmaceuticals, appointed as director and Chair of CervoMed Board effective Feb 7, 2024.
CervoMed expects to fully enroll RewinD-LB Phase 2b trial in 1H 2024; topline data for neflamapimod in DLB expected in 2H 2024.
Boger beneficially owns 561,309 shares (~9.90% of CRVO) and pre-funded warrants for 495,995 shares.
Dr. Sylvie Gregoire steps down as Chair but remains on Board.
Boger will receive 10,000 stock option grant and standard non-employee director compensation.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joshua S. Boger

Chair of the Board

CRVO · CervoMed Inc.

Effective: 2024-02-07
Filed: February 7, 2024, 6:59 PM ET

On February 5, 2024, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed Joshua S. Boger, Ph.D., as a director of the Company and as Chair of the Board, effective February 7, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua S. Boger was appointed as Chair of the Board at CervoMed Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

On February 5, 2024, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed Joshua S. Boger, Ph.D., as a director of the Company and as Chair of the Board, effective February 7, 2024.

View on SEC.gov

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-003357

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.